Clinical Trial Update: Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating concentration-controlled everolimus to eliminate or reduce tacrolimus compared with tacrolimus alone in de novo liver transplant reci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplantation

Drugs mentioned

• Everolimus (Afinitor) (everolimus)
• Tacrolimus (Prograf) (tacrolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Liver Transplantation | Phase 3 | Status: COMPLETED | Results posted: 2013-05-20